MY144471A - Use of oxycodone for treating visceral pain - Google Patents

Use of oxycodone for treating visceral pain

Info

Publication number
MY144471A
MY144471A MYPI20060082A MYPI20060082A MY144471A MY 144471 A MY144471 A MY 144471A MY PI20060082 A MYPI20060082 A MY PI20060082A MY PI20060082 A MYPI20060082 A MY PI20060082A MY 144471 A MY144471 A MY 144471A
Authority
MY
Malaysia
Prior art keywords
visceral pain
oxycodone
treating visceral
dosage
administering
Prior art date
Application number
MYPI20060082A
Other languages
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY144471(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MY144471A publication Critical patent/MY144471A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI20060082A 2005-01-18 2006-01-09 Use of oxycodone for treating visceral pain MY144471A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
MY144471A true MY144471A (en) 2011-09-30

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20060082A MY144471A (en) 2005-01-18 2006-01-09 Use of oxycodone for treating visceral pain

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20230170811A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE602006009899D1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)或抗降血鈣素基因相關胜肽受器(anti-cgrp-r)抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CA2595043A1 (en) 2006-07-27
PT1838318E (pt) 2009-12-15
KR20120089710A (ko) 2012-08-13
KR20070100368A (ko) 2007-10-10
KR20140091782A (ko) 2014-07-22
AU2006207498B2 (en) 2009-11-19
DE202006019887U1 (de) 2007-07-26
ES2333901T3 (es) 2010-03-02
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
US20150190393A1 (en) 2015-07-09
KR20200128451A (ko) 2020-11-12
NZ555852A (en) 2010-01-29
ATE446092T1 (de) 2009-11-15
CY1109660T1 (el) 2014-08-13
PL1838318T3 (pl) 2010-03-31
SI1838318T1 (sl) 2010-02-26
AU2006207498A1 (en) 2006-07-27
EA200701541A1 (ru) 2008-02-28
KR20190135557A (ko) 2019-12-06
KR20220165797A (ko) 2022-12-15
EP1838318B1 (en) 2009-10-21
AP2249A (en) 2011-07-18
DK200700207U3 (da) 2007-09-28
IL184530A0 (en) 2007-10-31
NO20074174L (no) 2007-10-17
AP2007004057A0 (en) 2007-08-31
JP5049139B2 (ja) 2012-10-17
KR20080106991A (ko) 2008-12-09
US20080200493A1 (en) 2008-08-21
EP1838318A1 (en) 2007-10-03
BRPI0606247A2 (pt) 2009-06-09
DK1838318T3 (da) 2010-01-04
AT9895U1 (de) 2008-05-15
AR052880A1 (es) 2007-04-11
ZA200705231B (en) 2008-06-25
WO2006077212A1 (en) 2006-07-27
DK200700207U1 (da) 2007-08-24
DE602006009899D1 (de) 2009-12-03
JP2008526927A (ja) 2008-07-24
KR20210131450A (ko) 2021-11-02
HRP20090679T1 (hr) 2010-01-31
CA2595043C (en) 2013-11-19
TW200637554A (en) 2006-11-01
KR20230170811A (ko) 2023-12-19
HK1107933A1 (en) 2008-04-25
CN101106996B (zh) 2013-10-23
NO338968B1 (no) 2016-11-07
RS51069B (sr) 2010-10-31
UA85471C2 (ru) 2009-01-26
CN101106996A (zh) 2008-01-16
ME01066B (me) 2012-10-20
US9271974B2 (en) 2016-03-01
EA013544B1 (ru) 2010-06-30
TWI432196B (zh) 2014-04-01

Similar Documents

Publication Publication Date Title
NO20074174L (no) Anvendelse av oksykodon for behandling av visceral smerte
AU2003216321A1 (en) Tamper-resistant transdermal opioid delivery devices
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
AU2003268144A8 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
MX2009010929A (es) Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer.
WO2007005716A3 (en) Methods of treatment and compositions for use thereof
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
CA2464768A1 (en) Method and composition for potentiating an opiate analgesic
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
NZ594486A (en) Narcotic emulsion opioid analgesic formulations for treatment of cancer pain
MX2008016520A (es) Medicamentos.
WO2007136615A3 (en) Combination cancer therapy
WO2008060381A3 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
TH85791A (th) วิธีการรักษาความเจ็บปวดอวัยวะภายใน
ATE380550T1 (de) Synergistische kombination eines opiatanalgetikums und eines nsaid
WO2009053804A3 (en) Idarubicin for the treatment of lymphoma in a dog
AU2003273114A1 (en) Medicament component of berberine for the use of prevention and treatment of psycological dependence on and analgesic tolerance to morphine
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego
WO2008015538A3 (en) Use of diaza- and thiaza-cycloalkanediones for preventing and/or treating pain and /or migraine